Venture Life Group (LON:VLG) Trading 9.7% Higher – Here’s What Happened

Venture Life Group plc (LON:VLG)’s stock price was up 9.7% on Wednesday . The company traded as high as GBX 62 and last traded at GBX 62. Approximately 195,728 shares were traded during mid-day trading, a decline of 32% from the average daily volume of 288,004 shares. The stock had previously closed at GBX 56.50.

Venture Life Group Trading Up 0.7%

The company has a debt-to-equity ratio of 0.82, a current ratio of 4.71 and a quick ratio of 1.48. The company has a market cap of £80.95 million, a price-to-earnings ratio of 15.21, a price-to-earnings-growth ratio of 5.67 and a beta of 0.24. The business has a 50 day simple moving average of GBX 61.03 and a 200 day simple moving average of GBX 64.15.

Venture Life Group (LON:VLG) last posted its quarterly earnings data on Tuesday, March 31st. The company reported GBX (1.49) EPS for the quarter. The business had revenue of GBX 3,517 million during the quarter. Venture Life Group had a return on equity of 7.82% and a net margin of 17.42%. As a group, equities analysts forecast that Venture Life Group plc will post 6.1391542 EPS for the current year.

Insider Buying and Selling at Venture Life Group

In other news, insider Paul McGreevy bought 15,663 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of GBX 64 per share, for a total transaction of £10,024.32. Insiders acquired a total of 80,207 shares of company stock worth $5,004,160 in the last ninety days. Insiders own 7.12% of the company’s stock.

About Venture Life Group

Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life.

Headquartered in the UK, the Group’s product portfolio includes Balance Activ in the area of women’s intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.